Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nuvation Bio Inc (NUVB)

Nuvation Bio Inc (NUVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Biotech Sector Advances in Pancreatic Cancer Research

USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working...

BRX : 22.28 (-0.18%)
ONCY : 1.1300 (-2.59%)
ONC.TO : 1.55 (-1.27%)
NVS : 102.69 (-0.51%)
IBRX : 7.75 (-4.32%)
ACRS : 1.1800 (unch)
NUVB : 3.41 (+3.33%)
Biotech’s Role in Addressing the Pancreatic Cancer Emergency

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END

NVX : 2.26 (-3.00%)
ONCY : 1.1300 (-2.59%)
ONC.TO : 1.55 (-1.27%)
NVS : 102.69 (-0.51%)
IBRX : 7.75 (-4.32%)
ACRS : 1.1800 (unch)
NUVB : 3.41 (+3.33%)
Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial...

NUVB : 3.41 (+3.33%)
Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial...

NUVB : 3.41 (+3.33%)
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced it has dosed...

NUVB : 3.41 (+3.33%)
Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial...

NUVB : 3.41 (+3.33%)
Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial...

NUVB : 3.41 (+3.33%)
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that it...

NUVB : 3.41 (+3.33%)
Nuvation Bio Inc. (NUVB) Upgraded to Buy: What Does It Mean for the Stock?

Nuvation Bio Inc. (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NUVB : 3.41 (+3.33%)
Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment...

NUVB : 3.41 (+3.33%)

Barchart Exclusives

Is It Too Late to Buy This Energy Dividend Stock at New Highs?
Here's a closer look at whether Constellation Energy's recent surge to record highs presents a lucrative opportunity to buy into the bullish momentum, or whether investors should practice caution at the current valuation. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar